Bora Pharmaceuticals
Tracked across 3 events · 20 articles · First seen May 12, 2026 · Last active Sep 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Bora Pharmaceuticals is acquiring the GMP manufacturing operations of MacroGenics, Inc. for US$122.5 million, strengthening its biologics CDMO platform in the United States.
May 12, 2026 · 6 articles
Business
Impact: Bora Pharmaceuticals completed the acquisition of MacroGenics' manufacturing operations, expanding its biologics CDMO capabilities and establishing a significant US manufacturing platform. This strengthens its position in the pharmaceutical services industry.
Jul 02, 2026 · 7 articles
Regulatory
Impact: Bora Pharmaceuticals, the licensor of TAVALISSE, may benefit from increased sales and royalties as Knight expands the drug's availability in Latin America.
Sep 01, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Bora Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard